Close
- Patent
- Trademark
- Innovation
- Legal Operations
- Localization
- Contact
More
- Learn & Support
- Learn and support
- Resource HubAccess value added content to support your IP strategy
- Webinars & EventsAre you interested in attending one of our online or onsite event?
- Product TrainingsCustomer success is our priority. Increase your skills in the use of Questel’s software
- Product NewsA platform dedicated to software and platforms news and evolutions
- eLearning ProgramsCreate engaging and custom corporate training programs
- Resource Hub
- About Questel
- Learn & Support
- Learn and support
- Resource HubAccess value added content to support your IP strategy
- Webinars & EventsAre you interested in attending one of our online or onsite event?
- Product TrainingsCustomer success is our priority. Increase your skills in the use of Questel’s software
- Product NewsA platform dedicated to software and platforms news and evolutions
- eLearning ProgramsCreate engaging and custom corporate training programs
- Resource Hub
- About Questel
EN
Webinar / Published, November 19, 2019
Do you have the rights to use CRISPR-based tools - Joint video with Genoway, Merck and Questel
overview
With more than 1200 patent families with claims including CRISPR, do you actually know whether you are infringing on third-party rights when using this technology?
Four industry experts provide meaningful insights and feedback in this webinar on the following topics:
- Use of CRISPR for model generation (Amélie Rezza, genOway)
- Overview of CRISPR patent landscape (Mathieu Fontaine, Questel)
- Coverage of specific Merck CRISPR-enabling process (Ajay Rastogi, Merck)
- Freedom to use CRISPR/Cas9-based tools (Sandrine Carteau, genOway)
Watch our video